Med Consumer Watch Study Identifies CoreAge Rx as High-Value Provider in GLP-1 Telehealth Sector
Med Consumer Watch released a comparative study reviewing 65 telehealth providers offering GLP-1 medications. The analysis found that CoreAge Rx offers transparent, flat-rate pricing starting at $99 per month for semaglutide and $149 per month for tirzepatide, without membership fees or hidden charges. The study also noted that CoreAge Rx provides care through board-certified physicians, indicating that affordable pricing and clinically supervised care can coexist in the GLP-1 telehealth market.
Telehealth GLP-1 Study
Savannah, GA, United States, 29th Jan 2026 – Med Consumer Watch, an independent healthcare consumer research organization, published a study comparing 65 telehealth providers offering GLP-1 medications. The analysis found that CoreAge Rx, a telehealth clinic focused on GLP-1 access for weight management and metabolic care, combines pricing transparency, clinical oversight, and affordability better than many peers.
The study, conducted in late 2025, evaluated providers on pricing structures, fee transparency, clinician qualifications, and telehealth delivery practices. CoreAge Rx stood out by offering clear, flat-rate monthly pricing. There are no membership fees or hidden costs. Pricing begins at $99 per month for semaglutide and $149 per month for tirzepatide. All care is provided under board-certified physician supervision.
GLP-1 Telehealth Insights
Med Consumer Watch’s analysis reflects increasing consumer demand for transparent and accessible care options within the expanding GLP-1 treatment market. GLP-1 medications, such as semaglutide and tirzepatide, are approved by regulatory authorities for metabolic and weight-related care and have seen rapid adoption across telehealth platforms. The report highlights variability in pricing models and clinical practices among the 65 providers analyzed, with CoreAge Rx scoring above average in key categories associated with consumer value.
In an objective summary of findings, the Med Consumer Watch report noted that CoreAge Rx’s pricing structure and clinical oversight suggest that patients can access medically supervised GLP-1 care without sacrificing affordability. The report emphasizes that transparent pricing and licensed clinician involvement are central to high-quality telehealth service delivery.
Telehealth Provider Analysis
The study’s methodology included an assessment of publicly available pricing information, consultation workflows, physician credentials, and telehealth care protocols. Med Consumer Watch maintains that its evaluations are intended to support informed health-care decision making and enhance market transparency for consumers comparing telehealth providers.
The full study is available for review on the Med Consumer Watch website, where readers can access a detailed breakdown of pricing tiers, provider features, and evaluation criteria. The release of this study aligns with ongoing efforts in the healthcare research community to monitor emerging care delivery models and their implications for patient access and affordability.
About Med Consumer Watch
Med Consumer Watch is an independent research organization dedicated to evaluating healthcare services and products with a focus on consumer interests. The organization conducts comparative analyses across medical and telehealth providers to support transparent, evidence-based information for the public.
Contact Information:
Med Consumer Watch
- Contact: Lisa Williams
- Email: lisa@medconsumerwatch.com
- Phone: +1 912-400-4927
- Website: https://www.medconsumerwatch.com/
CoreAge Rx Information:
- Company: CoreAge Rx
- Service Focus: Telehealth provider for GLP-1 medication access and metabolic care
- Pricing Highlights: Semaglutide from $99/month; Tirzepatide from $149/month
Company Details
Organization: Med Consumer Watch
Contact Person: Lisa Williams
Website: https://www.medconsumerwatch.com/
Email: Send Email
City: Savannah
State: GA
Country: United States
Release Id: 29012640740